Cargando…

Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies

Antidepressants are known to cause hyponatremia, but conflicting evidence exists regarding specific antidepressants. To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagashima, Takuya, Hayakawa, Takashi, Akimoto, Hayato, Minagawa, Kimino, Takahashi, Yasuo, Asai, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314855/
https://www.ncbi.nlm.nih.gov/pubmed/35258103
http://dx.doi.org/10.1002/cpt.2573
_version_ 1784754418516754432
author Nagashima, Takuya
Hayakawa, Takashi
Akimoto, Hayato
Minagawa, Kimino
Takahashi, Yasuo
Asai, Satoshi
author_facet Nagashima, Takuya
Hayakawa, Takashi
Akimoto, Hayato
Minagawa, Kimino
Takahashi, Yasuo
Asai, Satoshi
author_sort Nagashima, Takuya
collection PubMed
description Antidepressants are known to cause hyponatremia, but conflicting evidence exists regarding specific antidepressants. To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies. In the retrospective cohort study of patients (≥ 60 years) in Nihon University School of Medicine’s Clinical Data Warehouse (2004–2020), a significant decrease in serum sodium levels was observed within 30 days after initiation of a selective serotonin reuptake inhibitor (SSRI; mean change −1.00 ± 0.23 mmol/L, P < 0.001) or serotonin‐noradrenaline reuptake inhibitor (SNRI; −1.01 ± 0.31 mmol/L, P = 0.0013), whereas no decrease was found for a noradrenergic and specific serotonergic antidepressant (mirtazapine; +0.55 ± 0.47 mmol/L, P = 0.24). Within‐class comparison revealed no decrease in serum sodium levels for fluvoxamine (+0.74 ± 0.75 mmol/L, P = 0.33) among SSRIs and milnacipran (+0.08 ± 0.87 mmol/L, P = 0.93) among SNRIs. In the disproportionality analysis of patients (≥ 60 years) in the Japanese Adverse Drug Event Report database (2004–2020), a significant increase in hyponatremia reports was observed for SSRIs (reporting odds ratio 4.41, 95% confidence interval 3.58–5.45) and SNRIs (5.66, 4.38–7.31), but not for mirtazapine (1.08, 0.74–1.58), fluvoxamine (1.48, 0.94–2.32), and milnacipran (0.85, 0.45–1.62). Finally, pharmacoepidemiological–pharmacodynamic analysis revealed a significant correlation between the decrease in serum sodium levels and binding affinity for serotonin transporter (SERT; r = −0.84, P = 0.02), suggesting that lower binding affinity of mirtazapine, fluvoxamine, and milnacipran against SERT is responsible for the above difference. Although further research is needed, our data suggest that mirtazapine, fluvoxamine, and milnacipran are less likely to cause hyponatremia.
format Online
Article
Text
id pubmed-9314855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93148552022-07-27 Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies Nagashima, Takuya Hayakawa, Takashi Akimoto, Hayato Minagawa, Kimino Takahashi, Yasuo Asai, Satoshi Clin Pharmacol Ther Research Antidepressants are known to cause hyponatremia, but conflicting evidence exists regarding specific antidepressants. To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies. In the retrospective cohort study of patients (≥ 60 years) in Nihon University School of Medicine’s Clinical Data Warehouse (2004–2020), a significant decrease in serum sodium levels was observed within 30 days after initiation of a selective serotonin reuptake inhibitor (SSRI; mean change −1.00 ± 0.23 mmol/L, P < 0.001) or serotonin‐noradrenaline reuptake inhibitor (SNRI; −1.01 ± 0.31 mmol/L, P = 0.0013), whereas no decrease was found for a noradrenergic and specific serotonergic antidepressant (mirtazapine; +0.55 ± 0.47 mmol/L, P = 0.24). Within‐class comparison revealed no decrease in serum sodium levels for fluvoxamine (+0.74 ± 0.75 mmol/L, P = 0.33) among SSRIs and milnacipran (+0.08 ± 0.87 mmol/L, P = 0.93) among SNRIs. In the disproportionality analysis of patients (≥ 60 years) in the Japanese Adverse Drug Event Report database (2004–2020), a significant increase in hyponatremia reports was observed for SSRIs (reporting odds ratio 4.41, 95% confidence interval 3.58–5.45) and SNRIs (5.66, 4.38–7.31), but not for mirtazapine (1.08, 0.74–1.58), fluvoxamine (1.48, 0.94–2.32), and milnacipran (0.85, 0.45–1.62). Finally, pharmacoepidemiological–pharmacodynamic analysis revealed a significant correlation between the decrease in serum sodium levels and binding affinity for serotonin transporter (SERT; r = −0.84, P = 0.02), suggesting that lower binding affinity of mirtazapine, fluvoxamine, and milnacipran against SERT is responsible for the above difference. Although further research is needed, our data suggest that mirtazapine, fluvoxamine, and milnacipran are less likely to cause hyponatremia. John Wiley and Sons Inc. 2022-03-29 2022-06 /pmc/articles/PMC9314855/ /pubmed/35258103 http://dx.doi.org/10.1002/cpt.2573 Text en © 2022 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Nagashima, Takuya
Hayakawa, Takashi
Akimoto, Hayato
Minagawa, Kimino
Takahashi, Yasuo
Asai, Satoshi
Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title_full Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title_fullStr Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title_full_unstemmed Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title_short Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies
title_sort identifying antidepressants less likely to cause hyponatremia: triangulation of retrospective cohort, disproportionality, and pharmacodynamic studies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314855/
https://www.ncbi.nlm.nih.gov/pubmed/35258103
http://dx.doi.org/10.1002/cpt.2573
work_keys_str_mv AT nagashimatakuya identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies
AT hayakawatakashi identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies
AT akimotohayato identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies
AT minagawakimino identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies
AT takahashiyasuo identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies
AT asaisatoshi identifyingantidepressantslesslikelytocausehyponatremiatriangulationofretrospectivecohortdisproportionalityandpharmacodynamicstudies